Cantor Fitzgerald Has Positive View of MIRM FY2025 Earnings

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Stock analysts at Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for Mirum Pharmaceuticals in a research report issued on Thursday, August 7th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will earn ($1.00) per share for the year, up from their previous forecast of ($1.13). The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.43) per share. Cantor Fitzgerald also issued estimates for Mirum Pharmaceuticals’ FY2026 earnings at ($0.38) EPS.

Several other research analysts also recently issued reports on MIRM. Evercore ISI upped their price target on shares of Mirum Pharmaceuticals from $77.00 to $89.00 and gave the stock an “outperform” rating in a report on Friday. JMP Securities set a $81.00 price target on shares of Mirum Pharmaceuticals and gave the stock a “market outperform” rating in a report on Thursday, August 7th. HC Wainwright upped their price target on shares of Mirum Pharmaceuticals from $73.00 to $80.00 and gave the stock a “buy” rating in a report on Thursday, August 7th. Stifel Nicolaus set a $89.00 price target on shares of Mirum Pharmaceuticals and gave the stock a “buy” rating in a report on Monday. Finally, Wall Street Zen upgraded shares of Mirum Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $74.13.

Mirum Pharmaceuticals Stock Up 9.8%

Shares of NASDAQ:MIRM opened at $65.87 on Monday. The company has a fifty day moving average of $51.26 and a 200-day moving average of $47.30. The company has a market capitalization of $3.31 billion, a PE ratio of -54.44 and a beta of 0.94. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.97 and a current ratio of 3.13. Mirum Pharmaceuticals has a 52-week low of $36.86 and a 52-week high of $66.40.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.19. The company had revenue of $127.79 million during the quarter, compared to the consensus estimate of $107.91 million. Mirum Pharmaceuticals had a negative net margin of 13.65% and a negative return on equity of 24.76%. The company’s revenue for the quarter was up 64.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.52) earnings per share.

Institutional Trading of Mirum Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. CWM LLC boosted its position in Mirum Pharmaceuticals by 259.4% during the first quarter. CWM LLC now owns 593 shares of the company’s stock valued at $27,000 after acquiring an additional 428 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in Mirum Pharmaceuticals during the fourth quarter valued at $35,000. Comerica Bank boosted its position in Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after acquiring an additional 278 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in Mirum Pharmaceuticals during the fourth quarter valued at $42,000. Finally, Quarry LP bought a new stake in Mirum Pharmaceuticals during the first quarter valued at $56,000.

Insiders Place Their Bets

In related news, SVP Jolanda Howe sold 10,000 shares of the stock in a transaction on Thursday, August 7th. The stock was sold at an average price of $58.00, for a total value of $580,000.00. Following the completion of the sale, the senior vice president directly owned 2,426 shares in the company, valued at $140,708. This represents a 80.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Christopher Peetz sold 40,000 shares of the stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $55.25, for a total value of $2,210,000.00. Following the completion of the sale, the chief executive officer owned 138,641 shares of the company’s stock, valued at $7,659,915.25. The trade was a 22.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 51,041 shares of company stock valued at $2,840,624 over the last 90 days. 22.87% of the stock is currently owned by company insiders.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.